View Item 

Show simple item record

Antihypertensive Utility of Perindopril in a Large, General Practice-Based Clinical Trial

dc.contributor.authorJulius, Stevoen_US
dc.contributor.authorCohn, Jay N.en_US
dc.contributor.authorNeutel, Joelen_US
dc.contributor.authorWeber, Michaelen_US
dc.contributor.authorTurlapaty, Prasaden_US
dc.contributor.authorShen, Yannanen_US
dc.contributor.authorDong, Victoren_US
dc.contributor.authorBatchelor, Aliciaen_US
dc.contributor.authorLagast, Hjalmaren_US
dc.date.accessioned2010-06-01T19:48:09Z
dc.date.available2010-06-01T19:48:09Z
dc.date.issued2005-08en_US
dc.identifier.citationJulius, Stevo; Cohn, Jay N . ; Neutel, Joel; Weber, Michael; Turlapaty, Prasad; Shen, Yannan; Dong, Victor; Batchelor, Alicia; Lagast, Hjalmar (2005). "Antihypertensive Utility of Perindopril in a Large, General Practice-Based Clinical Trial." The Journal of Clinical Hypertension 7(s8): 10-17. <http://hdl.handle.net/2027.42/72935>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72935
dc.format.extent229888 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacq Ltd.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2004 Le Jacq Ltd.en_US
dc.titleAntihypertensive Utility of Perindopril in a Large, General Practice-Based Clinical Trialen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumthe Division of Hypertension, University of Michigan, Ann Arbor, MI;en_US
dc.contributor.affiliationotherthe Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN;en_US
dc.contributor.affiliationotherthe Orange County Heart Institute and Research Center, Orange, CA;en_US
dc.contributor.affiliationotherthe State University of New York Health Science Center, New York, NY;en_US
dc.contributor.affiliationotherSolvay Pharmaceuticals, Inc., Marietta, GAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72935/1/j.1524-6175.2004.04554.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2004.04554.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreferenceHansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998; 351: 1755 – 1762.en_US
dc.identifier.citedreferenceOliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002; 162: 413 – 420.en_US
dc.identifier.citedreferenceMancia G, Sega R, Milesi C, et al. Blood-pressure control in the hypertensive population. Lancet. 1997; 349: 454 – 457.en_US
dc.identifier.citedreferenceHalkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med. 2002; 112: 126 – 134.en_US
dc.identifier.citedreferenceHurst M, Jarvis B. Perindopril: an updated review of its use in hypertension. Drugs. 2001; 61: 867 – 896.en_US
dc.identifier.citedreferenceChrysant SG, McDonald RH, Wright JT, et al. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group. Clin Pharmacol Ther. 1993; 53: 479 – 484.en_US
dc.identifier.citedreferenceGregoire JP, Moisan J, Guibert R, et al. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001; 23: 715 – 726.en_US
dc.identifier.citedreferenceMesserli F, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002; 15: 550 – 556.en_US
dc.identifier.citedreferenceZannad F, Bernaud CM, Fay R. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group. J Hypertens. 1999; 17: 137 – 146.en_US
dc.identifier.citedreferenceOverlack A, Adamczac M, Bachmann W, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Am J Med. 1994; 97: 126 – 134.en_US
dc.identifier.citedreferenceMorgan TO, Louis WT, MacDonald GJ, et al. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. Am J Med. 1992; 92 ( suppl 4B ): 73S – 78S.en_US
dc.identifier.citedreference12 The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288: 2981 – 2997.en_US
dc.identifier.citedreference13 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 2413 – 2446.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2004.04554.x.pdf
Size:
224.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.